An axenic amastigote system for drug screening

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 818-822

  Callahan, Heather L ^a,b,c   Portal, Andréia C ^a   Devereaux, Robert ^b   Grogl, Max ^a,b  

^a US Army Med Research Unit Brazil   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c Amer Consulate Rio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MEGLUMINE ANTIMONATE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; STIBOGLUCONATE SODIUM;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG SCREENING; LEISHMANIA; LEISHMANIASIS; MACROPHAGE FUNCTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0030892248     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.818     Document Type: Article

References (74)

1. Al-Bashir, N., and M. Rassam. 1992. Axenic cultivation of amastigotes of Leishmania donovani and Leishmania major and their infectivity. Ann. Trop. Med. Parasitol. 86:487-502.
2. Allen, S., and R. Neal. 1989. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates, p. 711-720. In D. Hart (ed.), Leishmaniasis: the current status and new strategies for control. Plenum Press, New York.
3. Ashford, R., P. Desjeux, and P. deRaadt. 1992. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol. Today 8:104-105.
4. Assefa, D., Y. Worku, and G. Skoglund. 1995. Protein kinase activities in Leishmania aethiopica: control by growth, transformation and inhibitors. Biochim. Biophys. Acta 1270-157-162.
5. Bahr, V., Y.-D. Stierhof, T. Ilg, M. Demar, M. Quinten, and P. Overath. 1993. Expression of lipophosphoglycan, high-molecular weight phosphoglycan and glycoprotein 63 in promastigotes and amastigotes of Leishmania mexicana. Mol. Biochem. Parasitol. 58:107-122.
6. Bates, P. 1993. Characterization of developmentally-regulated nucleases in promastigotes and amastigotes of Leishmania mexicana. FEMS Microbiol. Lett. 107:53-58.
7. Bates, P. 1994. Complete developmental cycle of Leishmania mexicana in axenic culture. Parasitology 108:1-9.
8. Bates, P., C. Robertson, L. Tetley, and G. Coombs. 1992. Axenic cultivation and characterization of Leishmania mexicana amastigote-like forms. Parasitology 105:193-202.
9. Bates, P., and L. Tetley. 1993. Leishmania mexicana: induction of metacy- clogenesis by cultivation of promastigotes at acidic pH. Exp. Parasitol. 76: 412-423.
10. Bates, P. A. 1994. The developmental biology of Leishmania promastigotes. Exp. Parasitol. 79:215-218.
11. Bell, C., J. Hall, D. Kyle, M. Grogl, K. Ohemeng, M. Allen, and R. Tidwell. 1990. Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrob. Agents Chemother. 34:1381-1386.
12. Berg, K., L. Zhai, M. Chen, A. Kharmzmi, and T. Owen. 1994. The use of a water-soluble formazan complex to quantitate the cell number and mitochondrial function of Leishmania major promastigotes. Parasitol. Res. 80: 235-239.
13. Berman, J. 1985. Experimental chemotherapy of leishmaniasis - a critical review, p. 111-138. In C. Bray (ed.), Leishmaniasis. Elsevier Science Publishers B. V., Amsterdam.
14. Berman, J. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10:560-586.
15. Berman, J., J. Chulay, L. Hendricks, and C. Oster. 1982. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am. J. Trop. Med. Hyg. 31:459-465.
16. Berman, J., and J. Gallalee. 1985. Semiautomated assessment of in vitro activity of potential antileishmanial drugs. Antimicrob. Agents Chemother. 28:723-726.
17. Berman, J., J. Gallalee, and B. Hansen. 1987. Leishmania mexicana: uptake of sodium stibogluconate (Pentostam) and pentamidine by parasite and macrophages. Exp. Parasitol. 64:127-131.
18. Berman, J. D., and L. S. Lee. 1984. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J. Parasitol. 70:220-225.
19. Berman, J. D., and D. J. Wyler. 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J. Infect. Dis. 142:83-86.
20. Bernard, E., H. Donnelly, M. Maher, and D. Armstrong. 1985. Use of a new bioassay to study pentamidine pharmokinetics. J. Infect. Dis. 152:750-754.
21. Bijovsky, A. T. 1994. Leishmania mexicana: the influence of slightly elevated temperature on the ultrastructure of axenic amastigote-like forms. Parasitol. Res. 8:696-698.
22. Bodley, A., M. McGarry, and T. Shapiro. 1995. Drug cytotoxicity assay for African trypanosomes and Leishmania species. J. Infect. Dis. 172:1157-1159.
23. Bryceson, A., J. Chulay, M. Ho, M. Mugambii, J. Were, R. Muigal, C. Chunge, G. Gachihi, J. Meme, G. Anabwani, and S. Bhatt. 1985. Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans. R. Soc. Trop. Med. Hyg. 79:700-704.
24. Bryceson, A., J. Chulay, M. Mugambi, J. Were, G. Gachihi, C. Chunge, R. Muigai, S. Bhatt, M. Ho, H. Spencer, J. Meme, and G. Anabwani. 1985. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans. R. Soc. Trop. Med. Hyg. 79:705-714.
25. Callahan, H., C. Kelley, T. Pereira, and M. Grogl. 1996. Microtubule inhibitors: structure-activity analyses suggest rational models to identify potentially active compounds. Antimicrob. Agents Chemother. 40:947-952.
26. Callahan, H. L., and S. M. Beverley. 1991. Heavy metal resistance: a new role for P-glycoproteins in Leishmania. J. Biol. Chem. 266:18427-18430.
27. 1H] NMR characterization of amastigote-like forms. Mol. Cell. Biochem. 142:89-97.
28. Chang, K. 1980. Human cutaneous leishmaniasis in a mouse macrophage line: propagation and isolation of intracellular parasites. Science 209:1240-1244.
29. Charest, H., and G. Matlashewski. 1994. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote- stage-specific gene. Mol. Cell. Biol. 14:2975-2984.
30. Chulay, J., L. Fleckenstein, and D. Smith. 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg. 82:69-72.
31. Chunge, C., G. Gachihi, R. Muigai, K. Wasunna, J. Rashid, J. Chulay, G. Anabwani, C. Oster, and A. Bryceson. 1985. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans. R. Soc. Trop. Med. Hyg. 79:715-718.
32. Coombs, G., J. Craft, and D. Hart. 1982. A comparative study of Leishmania mexicana amastigotes and promastigotes. Enzyme activities and subcellular localizations. Mol. Biochem. Parasitol. 5:199-211.
33. 125Sb] sodium stibogluconate by Leishmania mexicana amazonensis and Leishmania donovani in vitro. Comp. Biochem. Physiol. 68C:95-98.
34. Dell, K., and J. Engel. 1994. Stage-specific regulation of protein phosphorylation in Leishmania major. Mol. Biochem. Parasitol. 64:283-292.
35. Doyle, P. S., J. C. Engel, P. Pimenta, P. Da Silva, and D. Dwyer. 1991. Leishmania donovani: long-term culture of axenic amastigotes at 37°C. Exp. Parasitol. 73:326-334.
36. Eperon, S., and D. McMahon-Pratt. 1989. I. Extracellular cultivation and morphological characterization of amastigote-like forms of Leishmania panamensis and Leishmania braziliensis. J. Protozool. 36:502-510.
37. Fong, D., M. M.-Y. Chan, R. Rodriguez, L. J. Gately, J. D. Berman, and M. Grogl. 1994. Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene. Am. J. Trop. Med. Hyg. 51:758-766.
38. Gebre-Hiwot, A., G. Yadesse, S. Crogt, and D. Frommel. 1992. An in vitro model for screening antileishmanial drugs: the human leukemia monocyte cell line, THP-1. Acta Trop. 51:237-245.
39. Grogl, M., A. M. J. Oduola, L. D. C. Cordero, and D. E. Kyle. 1989. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Exp. Parasitol. 69:78-90.
40. Grogl, M., T. N. Thomason, and E. D. Franke. 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:117-126.
41. Gueiros-Filho, F., and S. M. Beverley. 1994. On the introduction of genetically modified Leishmania outside the laboratory. Exp. Parasitol. 78:425-428.
42. Hart, D., and G. Coombs. 1982. Leishmania mexicana: energy metabolism of amastigotes and promastigotes. Exp. Parasitol. 54:397-409.
43. Ilg, T., D. Harbecke, and P. Overath. 1993. The lysosomal gp63-related protein in Leishmania mexicana amastigotes is a soluble metalloproteinase with an acidic pH optimum. FEBS Lett. 327:103-107.
44. Jackson, J., J. Tally, W. Ellis, Y. Mebrahtu, P. Lawyer, J. Were, S. Reed, D. Panisko, and B. Limmer. 1990. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. from patients unresponsive to pentavalent antimony therapy. Am. J. Trop. Med. Hyg. 43:464-480.
45. Jha, T., Y. Giri, T. Singh, and S. Jha. 1995. Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in North Bihar, India. Am. J. Trop. Med. Hyg. 52:536-538.
46. Lockwood, B., M. North, D. Mallinson, and G. Coombs. 1987. Analysis of Leishmania proteinases reveals developmental changes in species-specific forms and a common 68 kDa activity. FEMS Microbiol. Lett. 48:345-350.
47. Mattock, N., and W. Peters. 1975. The experimental chemotherapy of leishmaniasis. I. Techniques for the study of drug action in tissue culture. Ann. Trop. Med. Parasitol. 69:349-357.
48. Meade, J., T. Glaser, P. Bonventre, and A. Mukkada. 1984. Enzymes of carbohydrate metabolism in Leishmania donovani amastigotes. J. Protozool. 31:156-161.
49. Mebrahtu, Y., P. Lawyer, J. Githure, J. B. Were, R. Muigai, L. Hendricks, J. Leeuwenburg, D. Koech, and C. Roberts. 1989. Visceral leishmaniasis unresponsive to pentostam caused by Leishmania tropica in Kenya. Am. J. Trop. Med. Hyg. 41:289-294.
50. Moreira, E., J. Guerra, and M. Petrillo-Peixoto. 1992 Glucantime resistant Leishmania promastigotes are sensitive to pentostam. Rev. Soc. Bras. Med. Trop. 25:247-250.
51. Moreira, E., and M. Petrillo-Peixoto. 1991. In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania prormastigotes. Braz. J. Med. Biol. Res. 24:459-469.
52. Mottram, J., and G. Coombs. 1985. Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp. Parasitol. 59:151-160.
53. Neal, R., S. Allen, N. McCoy, P. Olliaro, and S. Croft. 1995. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35:577-584.
54. Neal, R. A. 1987. Experimental chemotherapy, p. 793-845. In W. Peters and R. Killick-Kendrick (ed.), The leishmaniases in biology and medicine. Academic Press, London.
55. Neal, R. A., and S. L. Croft. 1984. An in vitro system for determining the activity of compounds against the intracellular amastigote forms of Leishmania donovani. J. Antimicrob. Chemother. 14:463-475.
56. Nolan, L. L., and B. Bouchard. 1991. A rapid in vitro system for screening the effect of experimental compounds on nonadhering cell lines. Curr. Microbiol. 23:277-279.
57. North, M., and G. Coombs. 1981. Proteinases of Leishmania mexicana amastigotes and promastigotes: analysis by gel electrophoresis. Mol. Biochem. Parasitol. 3:293-300.
58. Pan, A. 1984. Leishmania mexicana: serial cultivation of intracellular stages in a cell-free medium. Exp. Parasitol. 58:72-80.
59. Pan, A., and S. Pan. 1986. Leishmania mexicana: comparative fine structure of amastigotes and promastigotes in vitro and in vivo. Exp. Parasitol. 62:254-265.
60. Pan, A. A., S. M. Duboise, S. Eperon, L. Rivas, V. Hodgkinson, Y. Traub- Cseko, and D. McMahon-Pratt. 1993. Developmental life cycle of Leishmania - cultivation and characterization of cultured extracellular amastigotes. J. Eukaryot. Microbiol. 40:213-223.
61. Pral, E. M. F., A. T. Bijovsky, J. M. F. Balanco, and S. C. Alfieri. 1993. Leishmania mexicana: proteinase activities and megasomes in axenically cultivated amastigote-like forms. Exp. Parasitol. 77:62-73.
62. Rainey, P., T. Spithill, D. McMahon-Pratt, and A. Pan. 1991. Biochemical and molecular characterization of Leishmania pifanoi amastigotes in continuous axenic culture. Mol. Biochem. Parasitol. 49:111-118.
63. Rees, P., M. Keating, P. Kager, and W. Hockmeyer. 1980. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet ii:226-229.
64. Roberts, W., J. Berman, and P. Rainey. 1995. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob. Agents Chemother. 39:1234-1239.
65. Roberts, W., and P. Rainey. 1993. Antileishmanial activity of sodium stibogluconate fractions. Antimicrob. Agents Chemother. 37:1842-1846.
66. Roberts, W. L., and P. M. Rainey. 1993. Antimony quantification in Leishmania by electrothermal atomic absorption spectroscopy. Anal. Biochem. 211:1-6.
67. Robertson, C., and G. Coombs. 1992. Stage-specific proteinases of Leishmania mexicana mexicana promastigotes. FEMS Microbiol. Lett. 94:127-132.
68. Robertson, C. D., and G. Coombs. 1990. Characterization of three groups of cysteine proteinases in the amastigotes of Leishmania mexicana mexicana. Mol. Biochem. Parasitol. 42:269-276.
69. Sacks, D., R. Kenney, R. Kreutzer, C. Jaffe, A. Gupta, M. Sharma, S. Sinha, F. Neva, and R. Saran. 1995. Indian kala-azar caused by Leishmania tropica. Lancet 345:959-961.
70. Schneider, P., J.-P. Rosat, J. Bouvier, J. Louis, and C. Bordier. 1992. Leishmania major: differential regulation of the surface metalloproteinase in amastigote and promastigote stages. Exp. Parasitol. 75:196-206.
71. Taylor, D., and G. Williams. 1992. Differentiation and limited proliferation of isolated Leishmania mexicana amastigotes at 27°C. Acta Trop. 50:141-150.
72. Thakur, C., M. Kumar, and A. Pandey. 1991. Comparison of regimes of treatment of antimony-resistant Kala-Azar patients: a randomised study. Am. J. Trop. Med. Hyg. 45:435-441.
73. Thakur, C., G. Sinha, A. Pandey, U. Barat, and P. Sinha. 1993. Amphotericin B in resistant kala-azar in Bihar. Natl. Med. J. India 6:57-60.
74. Ullman, B., E. Carrero-Valenzuela, and T. Coons. 1989. Leishmania donovani: isolation and characterization of sodium stibogluconate (Pentostam)- resistant cell lines. Exp. Parasitol. 69:157-163.